Loading...

Lisa Bero, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentClinical Pharmacy
Address533 Parnassus Avenue
San Francisco CA 94117
Phone415-476-1067
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    UCSF, Academic Senate2009Distinction in Mentoring Award
    Philip R. Lee Institute for Health Policy Studies, UCSF2009Harold Luft Award for Mentoring in Health Services and Health Policy Research
    McMaster University1998LaBelle Lectureship

    Collapse Overview 
    Collapse Overview
    Lisa A. Bero, PhD, Professor, Department of Clinical Pharmacy, School of Pharmacy and Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, is a pharmacologist with primary interests in how clinical and basic sciences are translated into clinical practice and health policy. She has developed and validated methods for assessing bias in the design, conduct and dissemination of research on pharmaceuticals, tobacco and chemicals. Dr. Bero has also conducted analyses to examine the dissemination and policy implications of research evidence. Her international activities include advisor to the World Health Organization Department of Essential Medicines and Pharmaceutical Policies, member and chair of the WHO Essential Medicines Committee and member of the Pan American Health Organization Advisory Committee on Health Research. She is Director of the San Francisco Branch of the United States Cochrane Center and the World Health Organization Collaborating Centre on Pharmaceutical Research and Science Policy. She was an elected member of the Cochrane Collaboration Steering Group for 12 years and was appointed Co-Chair in 2013. Dr. Bero serves on several national and international committees related to conflicts of interest and research, such as the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education and Practice.


    Collapse Research 
    Collapse Research Activities and Funding
    Measuring Design, Reporting and Funding Bias in Nonclinical Research
    NIH/NIEHS R21ES021028Sep 1, 2011 - Jul 31, 2014
    Role: Principal Investigator
    A Qualitative Study of Editorial Decision-Making
    NIH/NINDS R01NS044500Sep 15, 2002 - Aug 31, 2005
    Role: Principal Investigator
    Management Decisions in Financial Conflicts of Interest
    NIH/NINDS R01NS042398Sep 1, 2001 - Jul 31, 2004
    Role: Principal Investigator
    DEVELOPING POLICY TO REVERSE THE CIGAR TREND
    NIH/NCI R01CA076972Sep 30, 1997 - Sep 29, 2001
    Role: Principal Investigator
    MOLECULAR CHARACTERIZATION OF OPIATE BINDING SITES
    NIH/NIDA F32DA005327Feb 1, 1988
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Global Health
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Bero L. Ten tips for spotting industry involvement in science policy. Tob Control. 2018 Jun 25. PMID: 29941543.
      View in: PubMed
    2. Rezende LFM, Rey-López JP, Sá TH, Chartres N, Fabbri A, Powell L, Stamatakis E, Bero L. Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality. PLoS Biol. 2018 Jun 18; 16(6):e2005761. PMID: 29912869.
      View in: PubMed
    3. Wang Z, Norris SL, Bero L. The advantages and limitations of guideline adaptation frameworks. Implement Sci. 2018 May 29; 13(1):72. PMID: 29843737.
      View in: PubMed
    4. Bero L, Grundy Q. Not All Influences on Science Are Conflicts of Interest. Am J Public Health. 2018 May; 108(5):632-633. PMID: 29617619.
      View in: PubMed
    5. Parker L, Williams J, Bero L. Ethical drug marketing criteria for the 21st century. BMJ. 2018 Apr 30; 361:k1809. PMID: 29712644.
      View in: PubMed
    6. Bero L. Meta-research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust. PLoS Biol. 2018 Apr; 16(4):e2005972. PMID: 29608562.
      View in: PubMed
    7. Blake P, Durão S, Naude CE, Bero L. An analysis of methods used to synthesize evidence and grade recommendations in food-based dietary guidelines. Nutr Rev. 2018 Apr 01; 76(4):290-300. PMID: 29425371.
      View in: PubMed
    8. Mintzes B, Swandari S, Fabbri A, Grundy Q, Moynihan R, Bero L. Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study. BMJ Open. 2018 02 13; 8(2):e019027. PMID: 29440213.
      View in: PubMed
    9. Mahmic-Kaknjo M, Jelicic-Kadic A, Utrobicic A, Chan K, Bero L, Marušic A. Essential medicines availability is still suboptimal in many countries: A scoping review. J Clin Epidemiol. 2018 Feb 13. PMID: 29452222.
      View in: PubMed
    10. Grundy Q, Dunn AG, Bourgeois FT, Coiera E, Bero L. Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores. JAMA. 2018 01 23; 319(4):408-409. PMID: 29362787.
      View in: PubMed
    11. Bero L. Getting the systematic review basics right helps clinical practice: 4 common pitfalls for systematic review authors to avoid. Br J Sports Med. 2017 Dec 07. PMID: 29217534.
      View in: PubMed
    12. Bero L. Developing reliable dietary guidelines. BMJ. 2017 11 03; 359:j4845. PMID: 29101096.
      View in: PubMed
    13. Grundy Q, Held F, Bero L. A Social Network Analysis of the Financial Links Backing Health and Fitness Apps. Am J Public Health. 2017 Nov; 107(11):1783-1788. PMID: 28933939.
      View in: PubMed
    14. Chiu K, Grundy Q, Bero L. 'Spin' in published biomedical literature: A methodological systematic review. PLoS Biol. 2017 Sep; 15(9):e2002173. PMID: 28892482.
      View in: PubMed
    15. Fabbri A, Chartres N, Bero L. Study sponsorship and the nutrition research agenda: analysis of cohort studies examining the association between nutrition and obesity. Public Health Nutr. 2017 Dec; 20(17):3193-3199. PMID: 28851466.
      View in: PubMed
    16. Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E, Bero L. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open. 2017 Jun 30; 7(6):e016701. PMID: 28667226.
      View in: PubMed
    17. Grundy Q, Held FP, Bero L. Tracing the Potential Flow of Consumer Data: A Network Analysis of Prominent Health and Fitness Apps. J Med Internet Res. 2017 Jun 28; 19(6):e233. PMID: 28659254.
      View in: PubMed
    18. Walker J, Chaar BB, Vera N, Pillai AS, Lim JS, Bero L, Moles RJ. Medicine shortages in Fiji: A qualitative exploration of stakeholders' views. PLoS One. 2017; 12(6):e0178429. PMID: 28582409.
      View in: PubMed
    19. Cosgrove L, Shaughnessy AF, Peters SM, Lexchin JR, Bursztajn H, Bero L. Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychother Psychosom. 2017; 86(3):168-170. PMID: 28490018.
      View in: PubMed
    20. Bero L. Addressing Bias and Conflict of Interest Among Biomedical Researchers. JAMA. 2017 May 02; 317(17):1723-1724. PMID: 28464166.
      View in: PubMed
    21. Moynihan R, Bero L. Toward a Healthier Patient Voice: More Independence, Less Industry Funding. JAMA Intern Med. 2017 Mar 01; 177(3):350-351. PMID: 28114596.
      View in: PubMed
    22. Apollonio DE, Bero L. Interpretation and use of evidence in state policymaking: a qualitative analysis. BMJ Open. 2017 02 20; 7(2):e012738. PMID: 28219958.
      View in: PubMed
    23. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017 02 16; 2:MR000033. PMID: 28207928.
      View in: PubMed
    24. Lundh A, Bero L. The ties that bind. BMJ. 2017 Jan 17; 356:j176. PMID: 28096082.
      View in: PubMed
    25. Bero L, Grundy Q. Why Having a (Nonfinancial) Interest Is Not a Conflict of Interest. PLoS Biol. 2016 Dec; 14(12):e2001221. PMID: 28002462.
      View in: PubMed
    26. Fabbri A, Chartres N, Scrinis G, Bero L. Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity. Public Health Nutr. 2017 May; 20(7):1306-1313. PMID: 27989264.
      View in: PubMed
    27. Chartres N, Fabbri A, Bero L. Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016 Dec 01; 176(12):1769-1777. PMID: 27802480.
      View in: PubMed
    28. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016 11 23; 11:CD010274. PMID: 27878808.
      View in: PubMed
    29. Lawrence M, Naude C, Armstrong R, Bero L, Covic N, Durao S, Ghersi D, Macdonald G, MacLehose H, Margetts B, Tovey D, Volmink J, Young T. A call to action to reshape evidence synthesis and use for nutrition policy. Cochrane Database Syst Rev. 2016 Nov 21; 11:ED000118. PMID: 27883192.
      View in: PubMed
    30. Bero L. Systematic Review: A Method at Risk for Being Corrupted. Am J Public Health. 2017 Jan; 107(1):93-96. PMID: 27854519.
      View in: PubMed
    31. Grundy Q, Fabbri A, Mintzes B, Swandari S, Bero L. The Inclusion of Nurses in Pharmaceutical Industry-Sponsored Events: Guess Who Is Also Coming to Dinner? JAMA Intern Med. 2016 Nov 01; 176(11):1718-1720. PMID: 27617386.
      View in: PubMed
    32. Norris SL, Bero L. GRADE Methods for Guideline Development: Time to Evolve? Ann Intern Med. 2016 Dec 06; 165(11):810-811. PMID: 27654340.
      View in: PubMed
    33. Grundy QH, Wang Z, Bero L. Challenges in Assessing Mobile Health App Quality: A Systematic Review of Prevalent and Innovative Methods. Am J Prev Med. 2016 Dec; 51(6):1051-1059. PMID: 27659122.
      View in: PubMed
    34. Mandrioli D, Kearns CE, Bero L. Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews. PLoS One. 2016; 11(9):e0162198. PMID: 27606602; PMCID: PMC5015869.
    35. Apollonio DE, Wolfe N, Bero L. Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States. BMC Public Health. 2016 08 18; 16(1):822. PMID: 27539238; PMCID: PMC4991102.
    36. Vandenberg LN, Ågerstrand M, Beronius A, Beausoleil C, Bergman Å, Bero L, Bornehag CG, Boyer CS, Cooper GS, Cotgreave I, Gee D, Grandjean P, Guyton KZ, Hass U, Heindel JJ, Jobling S, Kidd KA, Kortenkamp A, Macleod MR, Martin OV, Norinder U, Scheringer M, Thayer KA, Toppari J, Whaley P, Woodruff TJ, Rudén C. A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals. Environ Health. 2016 07 14; 15(1):74. PMID: 27412149; PMCID: PMC4944316.
    37. Wang Z, Norris SL, Bero L. Implementation plans included in World Health Organisation guidelines. Implement Sci. 2016 05 20; 11(1):76. PMID: 27207104; PMCID: PMC4875699.
    38. Apollonio DE, Bero L. Challenges to generating evidence-informed policy and the role of systematic reviews and (perceived) conflicts of interest. J Commun Healthc. 2016; 9(2):135-141. PMID: 27721899.
      View in: PubMed
    39. Johnson PI, Koustas E, Vesterinen HM, Sutton P, Atchley DS, Kim AN, Campbell M, Donald JM, Sen S, Bero L, Zeise L, Woodruff TJ. Application of the Navigation Guide systematic review methodology to the evidence for developmental and reproductive toxicity of triclosan. Environ Int. 2016 Jul-Aug; 92-93:716-28. PMID: 27156197.
      View in: PubMed
    40. Grundy Q, Bero L, Malone RE. Marketing and the Most Trusted Profession: The Invisible Interactions Between Registered Nurses and Industry. Ann Intern Med. 2016 Jun 07; 164(11):733-9. PMID: 27043976.
      View in: PubMed
    41. Morgan RL, Thayer KA, Bero L, Bruce N, Falck-Ytter Y, Ghersi D, Guyatt G, Hooijmans C, Langendam M, Mandrioli D, Mustafa RA, Rehfuess EA, Rooney AA, Shea B, Silbergeld EK, Sutton P, Wolfe MS, Woodruff TJ, Verbeek JH, Holloway AC, Santesso N, Schünemann HJ. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ Int. 2016 Jul-Aug; 92-93:611-6. PMID: 26827182.
      View in: PubMed
    42. Elliott JH, Grimshaw J, Altman R, Bero L, Goodman SN, Henry D, Macleod M, Tovey D, Tugwell P, White H, Sim I. Informatics: Make sense of health data. Nature. 2015 Nov 05; 527(7576):31-2. PMID: 26536942.
      View in: PubMed
    43. Alexander PE, Gionfriddo MR, Li SA, Bero L, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Norris SL, Schünemann HJ, Thabane L, Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Feb; 70:111-22. PMID: 26399903.
      View in: PubMed
    44. Chang L, Dhruva SS, Chu J, Bero L, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ. 2015 Jun 10; 350:h2613. PMID: 26063311; PMCID: PMC4462712.
    45. Tran DN, Bero L. Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. J Glob Health. 2015 Jun; 5(1):010406. PMID: 25969730; PMCID: PMC4416332.
    46. Moynihan R, Nickel B, Hersch J, Beller E, Doust J, Compton S, Barratt A, Bero L, McCaffery K. Public Opinions about Overdiagnosis: A National Community Survey. PLoS One. 2015; 10(5):e0125165. PMID: 25992887; PMCID: PMC4439083.
    47. Schroll J, Bero L. Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev. 2015 Apr 20; 4:ED000098. PMID: 25904511.
      View in: PubMed
    48. Siler K, Lee K, Bero L. Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proc Natl Acad Sci U S A. 2015 Mar 31; 112(13):E1512. PMID: 25759436; PMCID: PMC4386344.
    49. Anglemyer AT, Krauth D, Bero L. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis. BMC Med Res Methodol. 2015 Mar 06; 15:12. PMID: 25880564; PMCID: PMC4353470.
    50. Chiu Y, Bero L, Hessol NA, Lexchin J, Harrington C. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015 Jun; 119(6):802-13. PMID: 25791166.
      View in: PubMed
    51. Hill SR, Bero L, McColl G, Roughead E. Expensive medicines: ensuring objective appraisal and equitable access. Bull World Health Organ. 2015 Jan 01; 93(1):4. PMID: 25558099; PMCID: PMC4271687.
    52. Siler K, Lee K, Bero L. Measuring the effectiveness of scientific gatekeeping. Proc Natl Acad Sci U S A. 2015 Jan 13; 112(2):360-5. PMID: 25535380; PMCID: PMC4299220.
    53. Alexander PE, Brito JP, Neumann I, Gionfriddo MR, Bero L, Djulbegovic B, Stoltzfus R, Montori VM, Norris SL, Schünemann HJ, Guyatt GH. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Apr; 72:98-106. PMID: 25618534.
      View in: PubMed
    54. Forsyth SR, Odierna DH, Krauth D, Bero L. Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles. Syst Rev. 2014 Nov 18; 3:122. PMID: 25417178; PMCID: PMC4241194.
    55. Bero L. Bias related to funding source in statin trials. BMJ. 2014 Oct 03; 349:g5949. PMID: 25281682.
      View in: PubMed
    56. Fox DM, Bero L. Systematic reviews: perhaps "the answer to policy makers' prayers"? Environ Health Perspect. 2014 Oct; 122(10):A262-3. PMID: 25272205; PMCID: PMC4181934.
    57. Magrini N, Robertson J, de Joncheere K, Bero L. On WHO's essential medicines process and transparency. BMJ. 2014 Sep 17; 349:g5637. PMID: 25231094.
      View in: PubMed
    58. Formoso G, Marata AM, Magrini N, Bero L. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014 Sep 15; (9):ED000090. PMID: 25228121.
      View in: PubMed
    59. Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol. 2015 Jan; 68(1):102-7. PMID: 25150193.
      View in: PubMed
    60. Bero L. What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. J Clin Epidemiol. 2014 Nov; 67(11):1239-41. PMID: 25132356.
      View in: PubMed
    61. Mahady SE, Schlub T, Bero L, Moher D, Tovey D, George J, Craig JC. Side effects are incompletely reported among systematic reviews in gastroenterology. J Clin Epidemiol. 2015 Feb; 68(2):144-53. PMID: 25124168.
      View in: PubMed
    62. Tovey D, Churchill R, Bero L. Evidence based medicine: looking forward and building on what we have learnt. BMJ. 2014 Jul 09; 349:g4508. PMID: 25008476.
      View in: PubMed
    63. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014 Apr 29; (4):MR000034. PMID: 24782322.
      View in: PubMed
    64. Abdel-Sattar M, Krauth D, Anglemyer A, Bero L. The Relationship between Risk of Bias Criteria, Research Outcomes, and Study Sponsorship in a Cohort of Preclinical Thiazolidinedione Animal Studies: A Meta-Analysis. Evid Based Preclin Med. 2014 Apr; 1(1):11-20. PMID: 25642330.
      View in: PubMed
    65. Coralic Z, Kanzaria HK, Bero L, Stein J. Staff perceptions of an on-site clinical pharmacist program in an academic emergency department after one year. West J Emerg Med. 2014 Mar; 15(2):205-10. PMID: 24672613; PMCID: PMC3966455.
    66. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria: Krauth et al. Respond. Environ Health Perspect. 2014 Mar; 122(3):A67. PMID: 24583480; PMCID: PMC3948043.
    67. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770. PMID: 24465178; PMCID: PMC3897361.
    68. Alexander PE, Bero L, Montori VM, Brito JP, Stoltzfus R, Djulbegovic B, Neumann I, Rave S, Guyatt G. World Health Organization recommendations are often strong based on low confidence in effect estimates. J Clin Epidemiol. 2014 Jun; 67(6):629-34. PMID: 24388966.
      View in: PubMed
    69. Odierna DH, Bero L. Retaining Participants in Outpatient and Community-Based Health Studies: Researchers and Participants in Their Own Words. Sage Open. 2014; 4(4):1-11. PMID: 25599003.
      View in: PubMed
    70. Bero L. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev. 2013 Dec 20; (12):ED000075. PMID: 24575439.
      View in: PubMed
    71. Chahal HS, St Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health. 2013 Dec; 3(2):020405. PMID: 24363923; PMCID: PMC3868824.
    72. Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero L, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med. 2013 Dec 9-23; 173(22):2032-6. PMID: 23925593.
      View in: PubMed
    73. Grundy Q, Bero L, Malone R. Interactions between non-physician clinicians and industry: a systematic review. PLoS Med. 2013 Nov; 10(11):e1001561. PMID: 24302892; PMCID: PMC3841103.
    74. Apollonio DE, Glantz SA, Bero L. Term limits and the tobacco industry. Soc Sci Med. 2014 Mar; 104:1-5. PMID: 24581055; PMCID: PMC4071941.
    75. Moynihan RN, Cooke GP, Doust JA, Bero L, Hill S, Glasziou PP. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 2013 Aug; 10(8):e1001500. PMID: 23966841; PMCID: PMC3742441.
    76. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect. 2013 Sep; 121(9):985-92. PMID: 23771496; PMCID: PMC3764080.
    77. Wolfe N, Gøtzsche PC, Bero L. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev. 2013 May 16; 2:31. PMID: 23680054; PMCID: PMC3685609.
    78. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ. 2013 Apr 23; 346:f2231. PMID: 23613540; PMCID: PMC3633324.
    79. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013 Apr 08; 173(7):580-1. PMID: 23440226.
      View in: PubMed
    80. Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43. PMID: 23400249.
      View in: PubMed
    81. Conway J, Bero L, Ondari C, Wasan KM. Review of the quality of pediatric medications in developing countries. J Pharm Sci. 2013 May; 102(5):1419-33. PMID: 23450511.
      View in: PubMed
    82. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013 Feb 28; (2):CD010398. PMID: 23450614.
      View in: PubMed
    83. Odierna DH, Forsyth SR, White J, Bero L. The cycle of bias in health research: a framework and toolbox for critical appraisal training. Account Res. 2013; 20(2):127-41. PMID: 23432773; PMCID: PMC3726025.
    84. Odierna DH, White J, Forsyth S, Bero L. Critical appraisal training increases understanding and confidence and enhances the use of evidence in diverse categories of learners. Health Expect. 2015 Apr; 18(2):273-87. PMID: 23252397.
      View in: PubMed
    85. Taba P, Rosenthal M, Habicht J, Tarien H, Mathiesen M, Hill S, Bero L. Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res. 2012 Dec 13; 12:455. PMID: 23234504; PMCID: PMC3532376.
    86. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012 Dec 12; 12:MR000033. PMID: 23235689.
      View in: PubMed
    87. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance abuse. Cochrane Libr. 2012 Dec 01; 12:1-10. PMID: 23833567.
      View in: PubMed
    88. Bero L, Busuttil G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Smith R, Tovey D. Measuring the performance of the Cochrane library. Cochrane Database Syst Rev. 2012 Nov 14; 12:ED000048. PMID: 23235688.
      View in: PubMed
    89. Bero L, Hill S, Habicht J, Mathiesen M, Starkopf J. The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. J Clin Epidemiol. 2013 Feb; 66(2):132-9. PMID: 22974497.
      View in: PubMed
    90. Bero L, Binder L. The Cochrane Collaboration review prioritization projects show that a variety of approaches successfully identify high-priority topics. J Clin Epidemiol. 2013 May; 66(5):472-3. PMID: 22959591.
      View in: PubMed
    91. Roseman M, Turner EH, Lexchin J, Coyne JC, Bero L, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012 Aug 16; 345:e5155. PMID: 22906823; PMCID: PMC3423635.
    92. Anson A, Ramay B, de Esparza AR, Bero L. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health. 2012 Jul 02; 8:22. PMID: 22747646; PMCID: PMC3503802.
    93. Hill S, Yang A, Bero L. Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One. 2012; 7(5):e38055. PMID: 22675435; PMCID: PMC3365009.
    94. Norris SL, Burda BU, Holmer HK, Ogden LA, Fu R, Bero L, Schünemann H, Deyo R. Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. J Clin Epidemiol. 2012 Jul; 65(7):725-33. PMID: 22498428.
      View in: PubMed
    95. Malone RE, Grundy Q, Bero L. Tobacco industry denormalisation as a tobacco control intervention: a review. Tob Control. 2012 Mar; 21(2):162-70. PMID: 22345240; PMCID: PMC3362192.
    96. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012 Jan 03; 344:d7202. PMID: 22214754.
      View in: PubMed
    97. Sutton P, Woodruff TJ, Vogel S, Bero L. Conrad and Becker's "10 Criteria" fall short of addressing conflicts of interest in chemical safety studies. Environ Health Perspect. 2011 Dec; 119(12):A506-7; author reply A508-9. PMID: 22134036; PMCID: PMC3261994.
    98. Walleser S, Hill SR, Bero L. Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. J Clin Epidemiol. 2011 Dec; 64(12):1331-40. PMID: 21775103.
      View in: PubMed
    99. Krleža-Jeriç K, Lemmens T, Reveiz L, Cuervo LG, Bero L. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Rev Panam Salud Publica. 2011 Jul; 30(1):87-96. PMID: 22159656.
      View in: PubMed
    100. Millar TP, Wong S, Odierna DH, Bero L. Applying the essential medicines concept to US preferred drug lists. Am J Public Health. 2011 Aug; 101(8):1444-8. PMID: 21680927; PMCID: PMC3134489.
    101. Roseman M, Milette K, Bero L, Coyne JC, Lexchin J, Turner EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011 Mar 09; 305(10):1008-17. PMID: 21386079.
      View in: PubMed
    102. Dhruva SS, Bero L, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011 Mar; 4(2):165-71. PMID: 21364127.
      View in: PubMed
    103. Smith R, Tovey D, Bero L, Busuttil G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Pais P. The Cochrane Library Oversight Committee. Cochrane Database Syst Rev. 2011 Feb 16; (8):ED000021. PMID: 21833980.
      View in: PubMed
    104. Bero L, Ghersi D. Making systematic reviews global. Cochrane Database Syst Rev. 2011 Feb 16; (8):ED000020. PMID: 21833979.
      View in: PubMed
    105. Ridge AL, Bero L, Hill SR. Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia. BMC Health Serv Res. 2010 Dec 16; 10:340. PMID: 21162717; PMCID: PMC3018452.
    106. Chen CE, Dhruva SS, Bero L, Redberg RF. Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies. Arch Intern Med. 2011 Mar 28; 171(6):534-9. PMID: 21098342.
      View in: PubMed
    107. Bero L, Carson B, Moller H, Hill S. To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008. Bull World Health Organ. 2010 Dec 01; 88(12):922-9. PMID: 21124717; PMCID: PMC2995193.
    108. Cataldo JK, Bero L, Malone RE. "A delicate diplomatic situation": tobacco industry efforts to gain control of the Framingham Study. J Clin Epidemiol. 2010 Aug; 63(8):841-53. PMID: 20630333; PMCID: PMC3046548.
    109. Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet. 2010 Jul 24; 376(9737):229-30. PMID: 20656114.
      View in: PubMed
    110. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, Bero L. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010 Jul 07; (7):CD000336. PMID: 20614422.
      View in: PubMed
    111. Robertson J, Walkom E, Moynihan R, Bero L, Henry D. Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract. 2010 Apr; 18(2):88-92. PMID: 20441117.
      View in: PubMed
    112. Dhruva SS, Bero L, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009 Dec 23; 302(24):2679-85. PMID: 20040556.
      View in: PubMed
    113. Rasmussen N, Lee K, Bero L. Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials. 2009 Dec 16; 10:116. PMID: 20015404; PMCID: PMC2811705.
    114. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009 Nov 12; 361(20):1963-71. PMID: 19907043.
      View in: PubMed
    115. Robertson J, Moynihan R, Walkom E, Bero L, Henry D. Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med. 2009 Nov; 6(11):e1000128. PMID: 19885393; PMCID: PMC2764857.
    116. Cook DM, Bero L. The politics of smoking in federal buildings: an executive order case study. Am J Public Health. 2009 Sep; 99(9):1588-95. PMID: 19608948; PMCID: PMC2724464.
    117. Apollonio DE, Bero L. Evidence and argument in policymaking: development of workplace smoking legislation. BMC Public Health. 2009 Jun 17; 9:189. PMID: 19534777; PMCID: PMC2706247.
    118. Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One. 2009 Jun 08; 4(6):e5826. PMID: 19503811; PMCID: PMC2688752.
    119. Odierna DH, Bero L. Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. J Clin Epidemiol. 2009 Dec; 62(12):1268-78. PMID: 19375890.
      View in: PubMed
    120. Nkansah N, Nguyen T, Iraninezhad H, Bero L. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr. 2009 Oct; 12(10):1931-7. PMID: 19254426.
      View in: PubMed
    121. Cook DM, Gurugubelli RK, Bero L. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf. 2009; 32(11):1057-66. PMID: 19810777.
      View in: PubMed
    122. White J, Bandura A, Bero L. Moral disengagement in the corporate world. Account Res. 2009 Jan-Mar; 16(1):41-74. PMID: 19247852.
      View in: PubMed
    123. Montini T, Bero L. Implementation of a workplace smoking ban in bars: the limits of local discretion. BMC Public Health. 2008 Dec 08; 8:402. PMID: 19063716; PMCID: PMC2633292.
    124. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008 Nov 25; 5(11):e217; discussion e217. PMID: 19067477; PMCID: PMC2586350.
    125. Bero L. "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise. J Clin Epidemiol. 2008 Jul; 61(7):629-33. PMID: 18538259.
      View in: PubMed
    126. Jewell CJ, Bero L. "Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government. Milbank Q. 2008 Jun; 86(2):177-208. PMID: 18522611; PMCID: PMC2690362.
    127. Finley PR, Bero L. Clarification of study and citation. Arch Intern Med. 2007 Dec 10; 167(22):2531; author reply 2531-2. PMID: 18071185.
      View in: PubMed
    128. Cook DM, Boyd EA, Grossmann C, Bero L. Reporting science and conflicts of interest in the lay press. PLoS One. 2007 Dec 05; 2(12):e1266. PMID: 18060060; PMCID: PMC2092382.
    129. Yank V, Rennie D, Bero L. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ. 2007 Dec 08; 335(7631):1202-5. PMID: 18024482; PMCID: PMC2128658.
    130. Boyd EA, Bero L. Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions. Sci Eng Ethics. 2007 Dec; 13(4):415-35. PMID: 18008185.
      View in: PubMed
    131. Prochaska JJ, Hall SM, Bero L. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? Schizophr Bull. 2008 May; 34(3):555-67. PMID: 17984298; PMCID: PMC2632440.
    132. White J, Parascandola M, Bero L. Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. Nicotine Tob Res. 2007 Nov; 9(11):1213-25. PMID: 17978997.
      View in: PubMed
    133. Apollonio DE, Lopipero P, Bero L. Participation and argument in legislative debate on statewide smoking restrictions. Health Res Policy Syst. 2007 Oct 22; 5:12. PMID: 17953767; PMCID: PMC2174461.
    134. Schick SF, Bero L, Cook DM. The tobacco industry and the Data Quality Act. Science. 2007 Aug 17; 317(5840):898. PMID: 17702925.
      View in: PubMed
    135. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007 Jun; 4(6):e184. PMID: 17550302; PMCID: PMC1885451.
    136. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero L. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007 Apr; 4(4):e134. PMID: 17455990; PMCID: PMC1855692.
    137. Apollonio DE, Bero L. The creation of industry front groups: the tobacco industry and "get government off our back". Am J Public Health. 2007 Mar; 97(3):419-27. PMID: 17267719; PMCID: PMC1805008.
    138. Dickersin K, Straus SE, Bero L. Evidence based medicine: increasing, not dictating, choice. BMJ. 2007 Jan 06; 334 Suppl 1:s10. PMID: 17204750.
      View in: PubMed
    139. Boyd EA, Bero L. Improving the use of research evidence in guideline development: 4. Managing conflicts of interests. Health Res Policy Syst. 2006 Dec 01; 4:16. PMID: 17140441; PMCID: PMC1693552.
    140. Steinman MA, Bero L, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006 Aug 15; 145(4):284-93. PMID: 16908919.
      View in: PubMed
    141. Nguyen NT, Cook DM, Bero L. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study. Clin Ther. 2006 Aug; 28(8):1231-1243. PMID: 16982301.
      View in: PubMed
    142. Lopipero P, Bero L. Tobacco interests or the public interest: 20 years of industry strategies to undermine airline smoking restrictions. Tob Control. 2006 Aug; 15(4):323-32. PMID: 16885582; PMCID: PMC2563596.
    143. Hong MK, Bero L. Tobacco industry sponsorship of a book and conflict of interest. Addiction. 2006 Aug; 101(8):1202-11. PMID: 16869850.
      View in: PubMed
    144. Lee KP, Boyd EA, Holroyd-Leduc JM, Bacchetti P, Bero L. Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust. 2006 Jun 19; 184(12):621-6. PMID: 16803442.
      View in: PubMed
    145. Cook DM, Bero L. Identifying carcinogens: the tobacco industry and regulatory politics in the United States. Int J Health Serv. 2006; 36(4):747-66. PMID: 17175844.
      View in: PubMed
    146. Glaser BE, Bero L. Attitudes of academic and clinical researchers toward financial ties in research: a systematic review. Sci Eng Ethics. 2005 Oct; 11(4):553-73. PMID: 16279755.
      View in: PubMed
    147. Cook DM, Tong EK, Glantz SA, Bero L. The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke. Health Aff (Millwood). 2005 Jul-Aug; 24(4):994-1004. PMID: 16136637.
      View in: PubMed
    148. Bero L. Tobacco industry manipulation of research. Public Health Rep. 2005 Mar-Apr; 120(2):200-8. PMID: 15842123; PMCID: PMC1497700.
    149. Baba A, Cook DM, McGarity TO, Bero L. Legislating "sound science": the role of the tobacco industry. Am J Public Health. 2005; 95 Suppl 1:S20-7. PMID: 16030333.
      View in: PubMed
    150. Bero L. Managing financial conflicts of interest in research. J Am Coll Dent. 2005; 72(2):4-9. PMID: 16353375.
      View in: PubMed
    151. Lipton S, Boyd EA, Bero L. Conflicts of interest in academic research: policies, processes, and attitudes. Account Res. 2004 Apr-Jun; 11(2):83-102. PMID: 15675050.
      View in: PubMed
    152. Boyd EA, Lipton S, Bero L. Implementation of financial disclosure policies to manage conflicts of interest. Health Aff (Millwood). 2004 Mar-Apr; 23(2):206-14. PMID: 15046145.
      View in: PubMed
    153. White J, Bero L. Public health under attack: the American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. Am J Public Health. 2004 Feb; 94(2):240-50. PMID: 14759933; PMCID: PMC1448234.
    154. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, Lee JY, Bero L. Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial. Pharmacotherapy. 2003 Sep; 23(9):1175-85. PMID: 14524649.
      View in: PubMed
    155. Boyd EA, Cho MK, Bero L. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med. 2003 Aug; 78(8):769-74. PMID: 12915362.
      View in: PubMed
    156. Lexchin J, Bero L, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31; 326(7400):1167-70. PMID: 12775614; PMCID: PMC156458.
    157. Bryan-Jones K, Bero L. Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule. Am J Public Health. 2003 Apr; 93(4):585-92. PMID: 12660202; PMCID: PMC1447795.
    158. Roth AL, Dunsby J, Bero L. Framing processes in public commentary on US federal tobacco control regulation. Soc Stud Sci. 2003 Feb; 33(1):7-44. PMID: 12918520.
      View in: PubMed
    159. Hong MK, Bero L. How the tobacco industry responded to an influential study of the health effects of secondhand smoke. BMJ. 2002 Dec 14; 325(7377):1413-6. PMID: 12480862; PMCID: PMC1124865.
    160. Beney J, Devine EB, Chow V, Ignoffo RJ, Mitsunaga L, Shahkarami M, McMillan A, Bero L. Effect of telephone follow-up on the physical well-being dimension of quality of life in patients with cancer. Pharmacotherapy. 2002 Oct; 22(10):1301-11. PMID: 12389880.
      View in: PubMed
    161. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, Bero L. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health Syst Pharm. 2002 Aug 15; 59(16):1518-26. PMID: 12185826.
      View in: PubMed
    162. Shamasunder B, Bero L. Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA. 2002 Aug 14; 288(6):738-44. PMID: 12169078.
      View in: PubMed
    163. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagin A, Yank V, MacLennan G, Gøtzsche PC, Bero L. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA. 2002 Jun 05; 287(21):2769-71. PMID: 12038907.
      View in: PubMed
    164. Rochon PA, Bero L, Bay AM, Gold JL, Dergal JM, Binns MA, Streiner DL, Gurwitz JH. Comparison of review articles published in peer-reviewed and throwaway journals. JAMA. 2002 Jun 05; 287(21):2853-6. PMID: 12038932.
      View in: PubMed
    165. Lee KP, Schotland M, Bacchetti P, Bero L. Association of journal quality indicators with methodological quality of clinical research articles. JAMA. 2002 Jun 05; 287(21):2805-8. PMID: 12038918.
      View in: PubMed
    166. Montini T, Mangurian C, Bero L. Assessing the evidence submitted in the development of a workplace smoking regulation: the case of Maryland. Public Health Rep. 2002 May-Jun; 117(3):291-8. PMID: 12432140; PMCID: PMC1497429.
    167. Ober M, Shohara R, Rennie D, Yank V, Bero L. The Criticism Management System for the Cochrane Library. Eval Health Prof. 2002 Mar; 25(1):98-115. PMID: 11868449.
      View in: PubMed
    168. Malone RE, Wenger LD, Bero L. High school journalists' perspectives on tobacco. J Health Commun. 2002 Mar-Apr; 7(2):139-56. PMID: 12049422.
      View in: PubMed
    169. Schotland MS, Bero L. Evaluating public commentary and scientific evidence submitted in the development of a risk assessment. Risk Anal. 2002 Feb; 22(1):131-40. PMID: 12017355.
      View in: PubMed
    170. Bero L. Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health. 2003; 24:267-88. PMID: 12415145.
      View in: PubMed